Jane F. Barlow, Matt W. Courtney, and Mark Trusheim of the FoCUS Project contributed the article to PharmExec.com, published January 9, 2020.
The reimbursement of emerging durable and potentially curative cell and gene therapies challenge U.S. payers due to their high upfront costs. In addition, the lack of long-term clinical durability data amplifies uncertainties which complicate payer coverage and reimbursement determinations. These cell and gene therapy characteristics could negatively impact patient access and ultimately, future developer innovation.